Search research articles
Contact Us
Filters
Showing results (181-190 of 198) with videos related to
Page
of 20
Sort By:
Current Pharmaceutical Biotechnology
|
April 18, 2025
A Comprehensive 4-Layered In Silico Pharmacogenomics Analysis of the Genetic Addiction Risk Severity (GARS) Test: Strong Genetic Evidence Supporting GARS as a Novel Personalized Pre-Addiction Assessment Tool in the Opioid Crisis Era
Alireza Sharafshah, Kai-Uwe Lewandrowski, Igor Elman, et al.
Medical Research Archives
|
October 27, 2023
Invited Expert Opinion- Bioinformatic and Limitation Directives to Help Adopt Genetic Addiction Risk Screening and Identify Preaddictive Reward Dysregulation: Required Analytic Evidence to Induce Dopamine Homeostatsis
Kenneth Blum, Mark S Gold, Jean Lud Cadet, et al.
British Journal of Sports Medicine
|
June 23, 2019
Infographic. Sleep disorders in athletes
Claudia L Reardon, Brian Hainline, Cindy Miller Aron, et al.
British Journal of Sports Medicine
|
July 17, 2019
Infographic: Mental health in elite athletes. An IOC consensus statement
Claudia L Reardon, Brian Hainline, Cindy Miller Aron, et al.
Current Neuropharmacology
|
January 27, 2025
In Silico Pharmacogenomic Assessment of Glucagon-like Peptide-1 (GLP1) Agonists and the Genetic Addiction Risk Score (GARS) Related Pathways: Implications for Suicide Ideation and Substance Use Disorder
Alireza Sharafshah, Kai-Uwe Lewandrowski, Mark S Gold, et al.
Acta Scientific Neurology
|
September 2, 2025
Dopaminergic Homeostatic Therapy (DHT<sup>™</sup>) as a Putative Anti-Addiction Seeking Intervention and Early Identification of Genetic Preaddiction with Genetic Addiction Risk Severity (GARS<sup>®</sup>) Screening
Kai-Uwe Lewandrowski, Abdalla Bowirrat, Albert Pinhasov, et al.
British Journal of Sports Medicine
|
May 18, 2019
Mental health in elite athletes: International Olympic Committee consensus statement (2019)
Claudia L Reardon, Brian Hainline, Cindy Miller Aron, et al.
Gene & Protein in Disease
|
May 20, 2024
Identification of stress-induced epigenetic methylation onto dopamine D2 gene and neurological and behavioral consequences
Kenneth Blum, Abdalla Bowirrat, David Baron, et al.
British Journal of Healthcare and Medical Research
|
May 8, 2026
Reward Deficiency Syndrome (RDS): A Common Neurogenetic Trait/State of All Addictions: Is this the new DSM?
Kenneth Blum, Kai Uwe Lewandrowski, Morgan P Lorio, et al.
Current Pharmaceutical Biotechnology
|
March 14, 2026
Pharmacogenomic-Based GWAS Meta-Analyses Coupled with Genetic and Epigenetic Liability Testing Connects Facial and Emotional Recognition Systems to Spectrum Disorders, Schizophrenia, Depression, and Anxiety
Kenneth Blum, Alexander P L Lewandrowski, Alireza Sharafshah, et al.
Page
of 20
Search research articles
Search
Showing results (181-190 of 198) with videos related to
Sort By:
Page
of 20
Current Pharmaceutical Biotechnology
|
April 18, 2025
A Comprehensive 4-Layered In Silico Pharmacogenomics Analysis of the Genetic Addiction Risk Severity (GARS) Test: Strong Genetic Evidence Supporting GARS as a Novel Personalized Pre-Addiction Assessment Tool in the Opioid Crisis Era
Alireza Sharafshah, Kai-Uwe Lewandrowski, Igor Elman, et al.
Medical Research Archives
|
October 27, 2023
Invited Expert Opinion- Bioinformatic and Limitation Directives to Help Adopt Genetic Addiction Risk Screening and Identify Preaddictive Reward Dysregulation: Required Analytic Evidence to Induce Dopamine Homeostatsis
Kenneth Blum, Mark S Gold, Jean Lud Cadet, et al.
British Journal of Sports Medicine
|
June 23, 2019
Infographic. Sleep disorders in athletes
Claudia L Reardon, Brian Hainline, Cindy Miller Aron, et al.
British Journal of Sports Medicine
|
July 17, 2019
Infographic: Mental health in elite athletes. An IOC consensus statement
Claudia L Reardon, Brian Hainline, Cindy Miller Aron, et al.
Current Neuropharmacology
|
January 27, 2025
In Silico Pharmacogenomic Assessment of Glucagon-like Peptide-1 (GLP1) Agonists and the Genetic Addiction Risk Score (GARS) Related Pathways: Implications for Suicide Ideation and Substance Use Disorder
Alireza Sharafshah, Kai-Uwe Lewandrowski, Mark S Gold, et al.
Acta Scientific Neurology
|
September 2, 2025
Dopaminergic Homeostatic Therapy (DHT<sup>™</sup>) as a Putative Anti-Addiction Seeking Intervention and Early Identification of Genetic Preaddiction with Genetic Addiction Risk Severity (GARS<sup>®</sup>) Screening
Kai-Uwe Lewandrowski, Abdalla Bowirrat, Albert Pinhasov, et al.
British Journal of Sports Medicine
|
May 18, 2019
Mental health in elite athletes: International Olympic Committee consensus statement (2019)
Claudia L Reardon, Brian Hainline, Cindy Miller Aron, et al.
Gene & Protein in Disease
|
May 20, 2024
Identification of stress-induced epigenetic methylation onto dopamine D2 gene and neurological and behavioral consequences
Kenneth Blum, Abdalla Bowirrat, David Baron, et al.
British Journal of Healthcare and Medical Research
|
May 8, 2026
Reward Deficiency Syndrome (RDS): A Common Neurogenetic Trait/State of All Addictions: Is this the new DSM?
Kenneth Blum, Kai Uwe Lewandrowski, Morgan P Lorio, et al.
Current Pharmaceutical Biotechnology
|
March 14, 2026
Pharmacogenomic-Based GWAS Meta-Analyses Coupled with Genetic and Epigenetic Liability Testing Connects Facial and Emotional Recognition Systems to Spectrum Disorders, Schizophrenia, Depression, and Anxiety
Kenneth Blum, Alexander P L Lewandrowski, Alireza Sharafshah, et al.
Page
of 20